Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 71Neoplasm Metastasis 26Stomach Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Colorectal Neoplasms 10Neoplasms 8Brain Neoplasms 8Adenocarcinoma 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Salivary Gland Neoplasms 3Recurrence 3HER2-positive Breast Cancer 3Advanced Solid Tumor 3Sarcoma 2Prostatic Neoplasms 2Neoplasm, Residual 2Meningeal Carcinomatosis 2Melanoma 2HER2-positive Gastric Cancer 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Breast Cancer With Brain Metastasis 2Advanced Breast Cancer 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1

Interventions

Cisplatin 161Fluorouracil 135Paclitaxel 127Radiotherapy 125Oxaliplatin 88Carboplatin 72Docetaxel 71Irinotecan 60pembrolizumab 57Leucovorin 57Capecitabine 57Radiation 48Esophagectomy 44Surgical Procedures, Operative 41Drug Therapy 38Neoadjuvant Therapy 28Cetuximab 25Nivolumab 24Bevacizumab 21camrelizumab 20Trastuzumab 20S 1 (combination) 19Chemoradiotherapy 19Magnetic Resonance Spectroscopy 18Epirubicin 16Albumin-Bound Paclitaxel 16Blood Specimen Collection 15tislelizumab 14Taxes 14Radiotherapy, Intensity-Modulated 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Esophageal Neoplasms × trastuzumab deruxtecan × Clear all
NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT04379596 2026-05-13

DG-03

AstraZeneca

Phase 2 Recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05480384 2026-04-21

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Brown University

Phase 2 Active not recruiting
1 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT05965479 2024-11-12

DECIPHER

University of Southampton

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡